Spironolactone dose‑dependently alleviates the calcification of aortic rings cultured in hyperphosphatemic medium with or without hyperglycemia by suppressing phenotypic transition of VSMCs through downregulation of Pit‑1

Wang,Ping; Quan,Zhengli; Luo,Dingshi; Chen,Wangshan; Peng,Dan

doi:10.3892/mmr.2019.10039

Spironolactone dose‑dependently alleviates the calcification of aortic rings cultured in hyperphosphatemic medium with or without hyperglycemia by suppressing phenotypic transition of VSMCs through downregulation of Pit‑1

Authors:
- Ping Wang
- Zhengli Quan
- Dingshi Luo
- Wangshan Chen
- Dan Peng
View Affiliations

Affiliations: Department of Nephrology, The First People's Hospital of Jingmen, Jingmen, Hubei 448000, P.R. China, Department of Neonatology, The First People's Hospital of Jingmen, Jingmen, Hubei 448000, P.R. China
Published online on: March 15, 2019 https://doi.org/10.3892/mmr.2019.10039
Pages: 3622-3632
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular calcification (VC) is highly prevalent in chronic kidney disease (CKD), especially in patients with end stage renal disease and is strongly associated with cardiovascular morbidity and mortality. Clinical observations have demonstrated that hyperphosphatemia and hyperglycemia can accelerate VC. Spironolactone (SPL) has been proven to improve cardiovascular outcomes in clinical trials and its protective effect on VC has been reported recently; however, the underlying mechanisms are not completely understood and require further investigation. Furthermore, the current CKD rat models that are used to research VC do not match well with the clinical characteristics of CKD patients. Aortic rings were obtained from male Sprague‑Dawley rats, then cultured in different media with varying phosphorus and glucose concentrations to investigate the effects and the possible mechanisms, as well as the effective serum concentrations of SPL, on VC and type III sodium‑dependent phosphate cotransporter‑1 (Pit‑1) expression. SPL dose‑dependently alleviated VC by suppressing the phenotypic transition of vascular smooth muscle cell (VSMCs) through downregulation of Pit‑1 in a high phosphorus medium and even in a high phosphorus combined with high glucose medium. The combined effects of hyperglycemia and hyperphosphatemia on the calcification of aortic rings ex vivo were demonstrated. In conclusion to the best of our knowledge, this article is the first report on the effective serum concentrations of SPL capable of protecting VSMCs from calcification and provides the first experimental evidence for the combined effects of hyperglycemia and hyperphosphatemia on VC of aortic rings. Additionally, the Pit‑1 protein level may be a novel index for evaluating the magnitude of VC in CKD patients.

View Figures

View References

1	Blacher J, Guerin AP, Pannier B, Marchais SJ and London GM: Arterial calcification, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 38:938–942. 2001. View Article : Google Scholar : PubMed/NCBI
2	Ohya M, Otain H, Kimura K, Saika Y, Fujii R, Yukawa S and Shigematsu T: Vascular calcification estimated by aortic calcification area index is significant predictive parameter of cardiovascular mortality in hemodialysis patients. Clin Exp Nephrol. 15:877–883. 2011. View Article : Google Scholar : PubMed/NCBI
3	London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B and Adda H: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 18:1731–1740. 2003. View Article : Google Scholar : PubMed/NCBI
4	Górriz JL, Molina P, Cerverón MJ, Vila R, Bover J, Nieto J, Barril G, Martínez-Castelao A, Fernández E, Escudero V, et al: Vascular calcification in patients with nondialysis CKD over 3 years. Clin J Am Soc Nephrol. 10:654–666. 2015. View Article : Google Scholar : PubMed/NCBI
5	Hruska KA, Mathew S, Lund R, Qiu P and Pratt R: Hyperphosphatemia of chronic kidney disease. Kidney Int. 74:148–157. 2008. View Article : Google Scholar : PubMed/NCBI
6	Demer LL and Tintut Y: Vascular calcification: Pathobiology of a multifaceted disease. Circulation. 117:2938–2948. 2008. View Article : Google Scholar : PubMed/NCBI
7	Giachelli CM: Vascular calcification mechanisms. J Am Soc Nephrol. 15:2959–2964. 2004. View Article : Google Scholar : PubMed/NCBI
8	Mizobuchi M, Tower D and Slatopolsky E: Vascular calcification: The killer of patients with chronic kidney disease. J Am Soc Nephrol. 20:1453–1464. 2009. View Article : Google Scholar : PubMed/NCBI
9	Shanahan CM, Crouthamel MH, Kapustin A and Giachelli CM: Arterial calcification in chronic kidney disease: Key roles for calcium and phosphate. Circ Res. 109:697–711. 2011. View Article : Google Scholar : PubMed/NCBI
10	Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G and Giachelli CM: Smooth muscle cell phenotypic transition associated with calcification: Upregulation of Cbfα1 and downregulation of smooth muscle lineage markers. Circ Res. 89:1147–1154. 2001. View Article : Google Scholar : PubMed/NCBI
11	Speer MY, Li X, Hiremath PG and Giachelli CM: Runx2/Cbfa1, but not loss of myocardin, is required for smooth muscle cell lineage reprogramming toward osteochondrogenesis. J Cell Biochem. 110:935–947. 2010. View Article : Google Scholar : PubMed/NCBI
12	Zhang J, Zheng B, Zhou PP, Zhang RN, He M, Yang Z and Wen JK: Vascular calcification is coupled with phenotypic conversion of vascular smooth muscle cells through Klf5-mediated transactivation of the Runx2 promoter. Biosci Rep. 34:e001482014. View Article : Google Scholar : PubMed/NCBI
13	Liao L, Zhuang X, Li W, Su Q, Zhao J and Liu Y: Polysaccharide from Fuzi protects against Ox-LDL-induced calcification of human vascular smooth muscle cells by increasing autophagic activity. Mol Med Rep. 17:5109–5115. 2018.PubMed/NCBI
14	Miyamoto K, Haito-sugino S, Kuwahara S, Ohi A, Nomura K, Ito M, Kuwahata M, Kido S, Tatsumi S, Kaneko I and Segawa H: Sodium-dependent phosphate cotransporters: Lessons from gene knockout and mutation studies. J Pharm Sci. 100:3719–3730. 2011. View Article : Google Scholar : PubMed/NCBI
15	Li X, Yang HY and Giachelli CM: Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res. 98:905–912. 2006. View Article : Google Scholar : PubMed/NCBI
16	Lau WL, Festing MH and Giachelli CM: Phosphate and vascular calcification: Emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb Haemost. 104:464–470. 2010. View Article : Google Scholar : PubMed/NCBI
17	Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J and Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 341:709–717. 1999. View Article : Google Scholar : PubMed/NCBI
18	Vizzardi E, D'Aloia A, Giubbini R, Bordonali T, Bugatti S, Pezzali N, Romeo A, Dei Cas A, Metra M and Dei Cas L: Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am J Cardiol. 106:1292–1296. 2010. View Article : Google Scholar : PubMed/NCBI
19	Brief M and Schiffrin EL: Vascular actions of aldosterone. J Vasc Res. 50:89–99. 2013. View Article : Google Scholar : PubMed/NCBI
20	McCurley A and Jaffe IZ: Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol. 350:256–265. 2012. View Article : Google Scholar : PubMed/NCBI
21	Wu SY, Yu YR, Cai Y, Jia LX, Wang X, Xiao CS, Tang CS and Qi YF: Endogenous aldosterone is involved in vascular calcification in rat. Exp Biol Med (Maywood). 237:31–37. 2012. View Article : Google Scholar : PubMed/NCBI
22	Jaffe IZ, Tintut Y, Newfell BG, Demer LL and Mendelsohn ME: Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol. 27:799–805. 2007. View Article : Google Scholar : PubMed/NCBI
23	Nitta K, Akiba T and Nihei H: Aldosterone blockade and vascular calcification in hemodialysis patients. Am J Med. 115:2502003. View Article : Google Scholar : PubMed/NCBI
24	Tatsumoto N, Yamada S, Tokumoto M, Eriguchi M, Noguchi H, Torisu K, Tsuruya K and Kitazono T: Spironolactone ameliorates arterial medial calcification in uremic rats: The roll of mineralocorticoid receptor signaling in vascular calcification. Am J Physiol Renal Physiol. 309:F967–F999. 2015. View Article : Google Scholar : PubMed/NCBI
25	Yokozawa T, Zheng PD, Oura H and Koizumi F: Animal model of adenine-induced chronic renal failure in rats. Nephron. 44:230–234. 1986. View Article : Google Scholar : PubMed/NCBI
26	Andrassy KM: Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease’. Kidney Int. 84:622–623. 2013. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Masumoto A, Sonou T, Ohya M, Yashiro M, Nakashima Y, Okuda K, Iwashita Y, Mima T, Negi S and Shigematsu T: Calcium overload accelerates phosphate-induced vascular calcification via Pit-1, but not the calcium-sensing receptor. J Atheroscler Thromb. 24:716–724. 2017. View Article : Google Scholar : PubMed/NCBI
29	Hwang IC, Park HE, Kim HL, Kim HM, Park JB, Yoon YE, Lee SP, Kim HK, Cho GY, Sohn DW and Kim YJ: Systemic inflammation is associated with coronary artery calcification and all-cause mortality in chronic kidney disease. Circ J. 80:1644–1652. 2016. View Article : Google Scholar : PubMed/NCBI
30	Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H and Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 87:E10–E17. 2000. View Article : Google Scholar : PubMed/NCBI
31	Yoshida T, Yamashita M and Hayashi M: Kruppel-like factor 4 contributes to high phosphate-induced phenotypic switching of vascular smooth muscle cells into osteogenic cells. J Biol Chem. 287:25706–25714. 2012. View Article : Google Scholar : PubMed/NCBI
32	Yoshida T, Yamashita M, Horimai C and Hayashi M: High glucose concentration does not modulate the formation of arterial medial calcification in experimental uremic rats. J Vasc Res. 50:512–520. 2013. View Article : Google Scholar : PubMed/NCBI
33	Ren X, Wei Q, Shao H, Sun Z and Liu N: A rat model of diabetic artery calcification. J Endocrinol Invest. 35:497–503. 2012.PubMed/NCBI
34	Wang P, Zhou P, Chen W and Peng D: Combined effects of hyperphosphatemia and hyperglycemia on the calcification of cultured human aortic smooth muscle cells. Exp Ther Med. 17:863–868. 2019.PubMed/NCBI
35	Jardine MJ, Hata J, Woodward M, Perkovic V, Ninomiya T, Arima H, Zoungas S, Cass A, Patel A, Marre M, et al: Prediction of kidney-related outcomes in patients with type 2 diabetes. Am J Kidney Dis. 60:770–778. 2012. View Article : Google Scholar : PubMed/NCBI
36	Leavitt BJ, Sheppard L, Maloney C, Clough RA, Braxton JH, Charlesworth DC, Weintraub RM, Hernandez F, Olmstead EM, Nugent WC, et al: Effects of diabetes and associated conditions on long-term survival after coronary artery bypass graft surgery. Circulation. 110 (11 suppl 1):II41–II44. 2004. View Article : Google Scholar : PubMed/NCBI
37	Wan EYF, Fong DYT, Fung CSC, Yu EYT, Chin WY, Chan AKC and Lam CLK: Prediction of new onset of end stage renal disease in Chinese patients with type 2 diabetes mellitus-a population-based retrospective cohort study. BMC Nephrol. 18:2572017. View Article : Google Scholar : PubMed/NCBI
38	Yang H, Curinga G and Giachelli CM: Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int. 66:2293–2299. 2004. View Article : Google Scholar : PubMed/NCBI
39	Villa-Bellosta R and Sorribas V: Phosphonoformic acid prevents vascular smooth muscle cell calcification by inhibiting calcium-phosphate deposition. Arterioscler Thromb Vasc Biol. 29:761–766. 1009. View Article : Google Scholar
40	Akiyoshi T, Ota H, Iijima K, Son BK, Kahyo T, Setou M, Ogawa S, Ouchi Y and Akishita M: A novel organ culture model of aorta for vascular calcification. Atherosclerosis. 244:51–58. 2016. View Article : Google Scholar : PubMed/NCBI
41	Suzuki A, Ghayor C, Guicheux J, Magne D, Quillard S, Kakita A, Ono Y, Miura Y, Oiso Y, Itoh M and Caverzasio J: Enhanced expression of the inorganic phosphate transporter Pit-1 is involved in BMP-2-induced matrix mineralization in osteoblast-like cells. J Bone Miner Res. 21:674–683. 2006. View Article : Google Scholar : PubMed/NCBI
42	Jaffe IZ and Mendelsohn ME: Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res. 96:643–650. 2005. View Article : Google Scholar : PubMed/NCBI
43	Voelkl J, Alesutan I, Leibrock CB, Quintanilla-Martinez L, Kuhn V, Feger M, Mia S, Ahmed MS, Rosenblatt KP, Kuro-O M and Lang F: Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Invest. 123:812–822. 2013.PubMed/NCBI
44	Kojima K, Yamamoto K, Fujioka H and Kaneko H: Pharmacokinetics of spironolactone and potassium canrenoate in humans. J Pharmacobiodyn. 8:161–166. 1985. View Article : Google Scholar : PubMed/NCBI
45	Overdiek HW, Hermens WA and Merkus FW: New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther. 38:469–474. 1985. View Article : Google Scholar : PubMed/NCBI
46	Terai I, Yamano K, Ichihara N, Arai J and Kobayashi K: Influence of spironolactone on neonatal screening for congenital adrenal hyperplasia. Arch Dis Child Fetal Neonatal Ed. 81:F179–F183. 1999. View Article : Google Scholar : PubMed/NCBI
47	Hayer MK, Edwards NC, Slinn G, Moody WE, Steeds RP, Ferro CJ, Price AM, Andujar C, Dutton M, Webster R, et al: A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial. Am Heart J. 191:37–46. 2017. View Article : Google Scholar : PubMed/NCBI
48	Hosoya K, Minakuchi H, Wakino S, Fujimura K, Hasegawa K, Komatsu M, Yoshifuji A, Futatsugi K, Shinozuka K, Washida N, et al: Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans. Kidney Int. 87:749–760. 2015. View Article : Google Scholar : PubMed/NCBI